Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06157567 · ClinicalTrials.gov registry record · NA
Clinical Feasibility Study to Evaluate the Safety and Performance of the Profound Matrix System
A NA study of Wrinkle and Skin Laxity, sponsored by Candela Corporation.
- Active
- Registry status
- NA
- Development phase
- 500
- Enrollment target
- 6
- Study locations
NCT06157567: Active NA study of Wrinkle and Skin Laxity, sponsored by Candela Corporation.
NCT06157567 is a NA study of Wrinkle and Skin Laxity that is active but no longer recruiting, run by Candela Corporation. The registered enrollment target is 500 participants, above the 100-participant average among 25 other Wrinkle trials with a reported enrollment target (400% higher). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06157567, a NA study of Wrinkle and Skin Laxity, is active but no longer recruiting, sponsored by Candela Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 500 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a non-randomized, multi-center, open-label clinical trial evaluating clinical feasibility treatments with the Profound Matrix system.
Primary Outcome
Clinical photography will be taken of treated areas at baseline prior to treatment and all treatment and follow-up visits.
Conditions Studied
Interventions
- DEVICE Profound Matrix
Study Locations (6)
Other
- Waterfront Skin and Laser - Vancouver
- Candela European Institue of Excellence - Madrid
Florida
- Center for Morden Aesthetic Medicine - Jacksonville
Massachusetts
- Candela Institue for Excellence - Marlborough
North Carolina
- Concierge Medical Arts - Fayetteville
Virginia
- Gerrish MedEsthetics - Vienna
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2022-05-24 |
| Est. Completion | 2028-05-24 |
| Phase | NA |
What the registry record for NCT06157567 still lists
NCT06157567 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 100-participant average among 25 other Wrinkle trials with a reported enrollment target (400% higher).
The record links to 3 conditions, with Wrinkle appearing as the primary indexed condition, and to 1 intervention - of which Profound Matrix is the first listed.
NCT06157567 lists 6 locations in 5 states (Other, Florida, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT06157567 about?
NCT06157567 is a clinical study titled "Clinical Feasibility Study to Evaluate the Safety and Performance of the Profound Matrix System". This is a non-randomized, multi-center, open-label clinical trial evaluating clinical feasibility treatments with the Profound Matrix system.
What is the current status of trial NCT06157567?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2022-05-24. Estimated completion is 2028-05-24.
What conditions does trial NCT06157567 study?
This clinical trial studies the following conditions: Wrinkle, Skin Laxity, Skin Condition.
What interventions are being tested in trial NCT06157567?
The interventions under investigation include: Profound Matrix (DEVICE).
Who is sponsoring clinical trial NCT06157567?
This trial is sponsored by Candela Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06157567 being conducted?
This trial has 6 study locations across Florida, Massachusetts, North Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wrinkle
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06157567's enrollment target sits among peer trials
500 1st of 25 higher than 23 of 25 other Wrinkle trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Wrinkle trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of Topical Almond Oil and Tretinoin on Facial Wrinkles
RECRUITING · NA
-
AVAVA MIRIA General Use
RECRUITING · NA
-
Feasibility Study to Collect and Assess Safety Data for a Radiofrequency Microneedling Device for Electrocoagulation and Hemostasis of Soft Tissues for Dermatologic Conditions
RECRUITING · NA
-
The Effects of Almond on Facial Skin Collagen and Wrinkles
RECRUITING · NA
-
A Prospective Controlled Study to Evaluate the Safety and Effectiveness of Thermage® FLX Radiofrequency Treatment
RECRUITING · NA
-
Clinical Study to Evaluate the Safety and Efficacy of Candela Technology
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI